Dose-dependent tumor growth inhibition was demonstrated in the HER2+ (IHC 3+ ) breast cancer models MMTV-HER2 Fo5, HCC1569 X2 cell line and WHIM8 PDX model (Fig. 4a), as well as in HER2+ (IHC 3+ ) gastric cancer PDX models STO410 and STO41 (Fig. 4b, see Supplementary Fig. 12 for HER2 IHC for these models). Here, ERBB2 is linked to breast carcinoma.